Results from a series of HIV vaccine Phase IIa clinical trials, using a plasmid DNA vaccine developed by the NIH Vaccine Research Center and manufactured by Vical, reinforced Phase I conclusions that a DNA prime-adenoviral vector boost vaccine regimen was safe and well-tolerated, and effective in inducing T-cell immune responses in up to 70 percent of the vaccine recipients, Vical reported.
According to Vical, the trials involved priming an immune response with three doses of a plasmid DNA vaccine over a two-month period and boosting the response with a single dose of adenoviral vector vaccine at six months.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment